April 6, 2020
Episode 6 - Science at Work
We highlight a Purdue biochemistry professor and his team's work to fight against the COVID-19 pandemic. Also, a father and son team share how their startup can help elderly patients suffering from hip fractures.
Seven days a week, Purdue University biochemistry professor Andrew Mesecar and his research team are currently working long hours in the fight against the current coronavirus. Since 2003, he and his colleague Arun Ghosh have been making strides in studies of coronaviruses, and hope their work will help prevent future coronavirus outbreaks.
In Part 1 of this episode, we talk about their work and the goals of their interdisciplinary team, including the goal to help efforts to catalog existing compounds that could treat COVID-19 patients, if not in this outbreak, possibly in future outbreaks that would precede the availability of a vaccine.
In Part 2, father and son team, Phillip and Stewart Low, tell us how they use their scientific knowledge to create an injectable drug that solely targets bone fractures through their startup, Novosteo Inc. This new drug is designed to help elderly patients suffering from hip fractures, with possible applications to other health issues such as a treatment for bone infections. Though the road to creating a startup was challenging, the two College of Science researchers reflect on how their father-son relationship is one of the keys to the success of Novosteo and its potential impact.
These Boilermakers are living up to their Purdue potential. They are building a better world together.
After you hear their stories, please connect with us on our social pages to share your reaction.